Glioblastoma

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

Retrieved on: 
Freitag, Mai 17, 2024
Probability, RAS, Patient, Metabolism, ADME, Rasm, Glioblastoma, NDA, MAPK, Clinical trial, Neoplasm, BIC, ASCO, CRC, ID, Pharmaceutical industry

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced it has entered into exclusive license agreements for two preclinical RAS programs—a potential best-in-class pan-RAS molecular glue (ERAS-0015) and a potential first-in-class pan-KRAS inhibitor (ERAS-4001)—and provided a pipeline update. ERAS-0015 and ERAS-4001 are highly potent, orally bioavailable molecules with complementary RAS inhibitory mechanisms that have the potential to address unmet needs in nearly 2.7 million patients who are diagnosed annually globally with RAS-mutant (RASm) tumors, of which over 2.2 million patients are diagnosed with KRAS-mutant (KRASm) tumors.

Key Points: 
  • As separately announced, Erasca has priced an equity offering of $160 million with a high quality group of new and existing healthcare-focused investors.
  • “We’re thrilled to add ERAS-0015 and ERAS-4001 to our pipeline.
  • This is undoubtedly a challenging time for our highly talented employees, particularly those affected by these changes.
  • The live webcast and replay may be accessed by visiting Erasca’s website at Erasca.com/events .

Shuttle Pharma Provides First Quarter 2024 Corporate Update

Retrieved on: 
Dienstag, Mai 14, 2024
Patient, Prognosis, Planet, Survival, Glioblastoma, Food, Letter, HERE, Diagnosis, FDA, Radiation, Indian stock exchange, Prostate cancer, Cancer, Research, HDAC6, Brain, Therapy, Quality of life, RT, IRB, Georgetown University

GAITHERSBURG, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the first quarter ended March 31, 2024.

Key Points: 
  • GAITHERSBURG, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the first quarter ended March 31, 2024.
  • Finalizing site enrollment with up to six institutions with ‘first patient, first dose’ expected in the second quarter of 2024.
  • Created Shuttle Diagnostics, Inc., a wholly owned subsidiary of Shuttle Pharma, which will focus on developing a diagnostics laboratory to develop its metabolite discovery platform technology and to support multi-institutional clinical trials.
  • Anatoly Dritschilo, M.D., Chief Executive Officer of Shuttle Pharma, participated in a presentation at the Planet MicroCap Showcase: VEGAS 2024 on May 1, 2023.

VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

Retrieved on: 
Mittwoch, Mai 22, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, GBM, Patient, VBI, Vaccine, Toxicity, Glioblastoma, Disease, ASCO, Society, Combination therapy, Annual general meeting, Pharmaceutical industry

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were accepted for poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were accepted for poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • The presentation at ASCO will provide an update to the encouraging data previously shared at the World Vaccine Congress Washington in April , including additional data from those initially evaluable patients, as well as data from new patients who have since been randomized into the Phase 2b study.
  • Patients will be randomized in a 1:1 ratio across two study arms:
    Monotherapy standard-of-care: either intravenous carmustine or oral lomustine, every 6 weeks until disease progression or intolerable toxicity

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Donnerstag, Mai 9, 2024
Financial management, FDA, University, Cancer, FOLFIRINOX, Temozolomide, CendR, Safety, Pancreatic cancer, Conference call, Research, RNA, Osteosarcoma, GBM, National Health, Tumor microenvironment, PDAC, Therapy, Patient, SOC, Neoplasm, Data analysis, Glioblastoma, Projection, Pharmaceutical industry

BASKING RIDGE, N. J., May 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the three months ended March 31, 2024.

Key Points: 
  • “2024, a pivotal year for Lisata, is off to a very strong start,” stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata.
  • The trial is actively enrolling with enrollment completion expected by the end of the third quarter of 2024.
  • As of March 31, 2024, Lisata had cash, cash equivalents, and marketable securities of approximately $43.3 million.
  • Lisata will hold a live conference call today, May 9, 2024, at 4:30 p.m. Eastern Time to discuss financial results, provide a business update and answer questions.

Brain Cancer Canada awards The Dwayne Andrews Glioblastoma Grant for Research to a study on the impact of anesthetics on brain cancer proliferation

Retrieved on: 
Mittwoch, Mai 8, 2024
Family, Research, SAC, Glioblastoma, Patient safety, Brain, Patient, Metastasis, Anesthetic, LHSC, Lawson Health Research Institute, London Health Sciences Centre, Neuro, Medical imaging

The grant will fund a study at London Health Sciences Centre (LHSC) titled “Comparison of intravenous and inhaled anesthetics on brain tumour proliferation: an in-vitro study”.

Key Points: 
  • The grant will fund a study at London Health Sciences Centre (LHSC) titled “Comparison of intravenous and inhaled anesthetics on brain tumour proliferation: an in-vitro study”.
  • The work aims to assess whether anesthetics used during glioblastoma brain tumour surgery can impact tumour growth, invasion, and metastasis.
  • This grant reflects our commitment to supporting innovative research that can lead to better outcomes for brain cancer patients," she said.
  • Our team thanks Brain Cancer Canada, the Andrews Family and Auto|One Group for helping us kickstart our work through the Dwayne Andrews GBM Research Grant.”
    The grant is the first in a series of four to be issued by Brain Cancer Canada during May, Brain Cancer Awareness Month.

Vect-Horus to Take Part in a Roundtable Discussion at Viva Technology Conference

Retrieved on: 
Dienstag, Mai 7, 2024
Brain, Scientific method, Ionis Pharmaceuticals, Pancreatic cancer, Glioblastoma, Novo Nordisk, Viva Technology, Clinical trial, CNRS, Cancer, Biotechnology, Pharmaceutical industry

For this event, France’s National Center for Scientific Research (CNRS) has decided to highlight 10 start-ups developing disruptive technologies.

Key Points: 
  • For this event, France’s National Center for Scientific Research (CNRS) has decided to highlight 10 start-ups developing disruptive technologies.
  • In the field of Health, Vect-Horus has been selected to present its VECTrans® technology, unique in Europe, which represents a breakthrough innovation in drug targeting to the brain and other pathological tissues (e.g.
  • Vect-Horus Chief Scientific Officer Jean-Manuel Pean will take part in a roundtable, where he will present an overview of the Company and its pipeline.
  • More details on the definite roundtable program will be announced closer to the event.

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Retrieved on: 
Mittwoch, Mai 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, FXI, MTAP, Mutation, Safety, PARP, Pharmacokinetics, Carcinoma, Breast, STK11, BID, GBM, Glioblastoma, Culture, Journal, Novartis, Patient, Medicinal chemistry, Cancer, Collaboration, Clinical trial, Therapy, NSCLC, PRMT5, Pharmaceutical industry

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2024, and provided business highlights.

Key Points: 
  • Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2024, and provided business highlights.
  • Finally, we welcomed the newest member of our leadership team, Julie Carretero, as Chief Human Resources Officer.
  • Dose expansion is expected to initiate in the TNG462 phase 1/2 clinical trial in 2Q 2024.
  • General and administrative expenses were $10.7 million for the three months ended March 31, 2024, compared to $8.0 million for the same period in 2023.

BPGbio Brings Late Clinical Stage Rare Disease and Oncology Assets to US and EU Pharma Partnering Summits

Retrieved on: 
Dienstag, Mai 7, 2024
Software, Research, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Neurology, FDA, Health, Breast cancer, Brain, Q10, HPC, Parkinson's disease, Carcinoma, Liver disease, Oak Ridge National Laboratory, State, Pancreatic cancer, Doctor of Philosophy, Tumor microenvironment, GBM, Epidermolysis bullosa, SCC, Therapy, Patient, Sarcopenia, Glioblastoma, Biomarker, Drug discovery, Orphan drug, EB, TME, Pharmaceutical industry

BPGbio’s executives, including Daniel Elliott , Board Member and Chief Commercial Advisor, plan to share details of the company’s commercial ready assets.

Key Points: 
  • BPGbio’s executives, including Daniel Elliott , Board Member and Chief Commercial Advisor, plan to share details of the company’s commercial ready assets.
  • BPM31510 acts by targeting the mitochondrial machinery and tumor microenvironment (TME) to create a metabolic shift in cancer cells, leading to cancer cell death.
  • BPGbio is also exploring a late stage trial with BPM31510-IV/oral for primary coenzyme Q10 deficiency , an ultra-rare, potentially life threatening disease that affects the brain, muscles, and kidneys in afflicted patients.
  • This platform identifies targets, biomarkers, and drugs and assists the development team through both the development and clinical trial stages.

Strengthening CAR-T Therapy to Work Against Solid Tumors

Retrieved on: 
Mittwoch, Mai 8, 2024
Immunotherapy, Brain, University, Blood, Prostate, Protein, Mouse, Pancreas, Ovary, Safety, Public health, See, Cancer research, Glioblastoma, Genetic engineering, Invention, TMIGD2, Canadian Aviation Regulations, Urology, National Cancer Institute, Research, Leukemia, Chimera, Lymphoma, CD276, Liver, Microbiology, Medicine, Bone marrow, Neoplasm, Lung, Paper, Antigen, Zang, Immune system, Albert Einstein, Vaccine

"CAR-T cell therapy has revolutionized the treatment of blood cancers such as leukemia and lymphoma but hasn't worked well against solid tumors," said Xingxing Zang, Ph.D. , the paper's senior author.

Key Points: 
  • "CAR-T cell therapy has revolutionized the treatment of blood cancers such as leukemia and lymphoma but hasn't worked well against solid tumors," said Xingxing Zang, Ph.D. , the paper's senior author.
  • "We found that our changes to standard CAR-T cell therapy can significantly boost its effectiveness against solid tumors, including often-fatal pancreatic cancer and glioblastomas."
  • Dr. Zang and his colleagues created five CAR-T therapies that they tested on mice implanted with several types of solid human tumors.
  • He later realized that incorporating TMIGD2 into CAR-T cells might enable them to overcome the challenges posed by solid tumors.

CIRM Awards $11.8 Million Grant for Clinical Trial in High-Grade Glioma Including Glioblastoma Using DB107, a Novel DGM7™ Genetic Biomarker-Guided Gene Therapy

Retrieved on: 
Dienstag, April 30, 2024
University of Southern California, Efficacy, University, UCSD, Radiation, Resection, Regenerative medicine, HGG, TMZ, Doctor of Philosophy, RRV, GBM, WGS, Glioblastoma, Artificial intelligence, Depression, CIRM, UCSF, USC, Intravenous therapy, Neoplasm, Clinical trial, Medicine, SHROOM3, Whole genome sequencing, SAN, Medical imaging

We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.

Key Points: 
  • We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.
  • DB107 consists of two components: DB107–RRV (vocimagene amiretrorepvec) as a prodrug activator gene therapy and DB107–FC (extended-release 5–fluorocytosine [5–FC]) as an oral prodrug.
  • Retrospective analysis of an earlier randomized clinical trial in patients with recurrent HGG suggested improved overall survival in DGM7–positive patients treated with DB107.
  • "We are excited to conduct this novel trial which will be investigating several new approaches for the first time in patients with newly–diagnosed high–grade glioma.